Pfizer Net Change in Cash decreased by 241.3% to -$301.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 1137.9%, from $29.00M to -$301.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests the company is accumulating liquidity, while a decrease indicates it spent more on investments, debt repayment, or operations than it generated in cash.
This metric represents the total increase or decrease in a company's cash, cash equivalents, and restricted cash over a...
This is a universal accounting standard used to reconcile the cash flow statement to the balance sheet across all industries and global peers.
cf_net_change_in_cash| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $608.00M | -$384.00M | $529.00M | -$688.00M | -$487.00M | -$869.00M | $1.75B | $475.00M | $535.00M | -$2.14B | $343.00M | $29.00M | -$45.00M | $375.00M | $213.00M | -$301.00M |
| QoQ Change | — | -163.2% | +237.8% | -230.1% | +29.2% | -78.4% | +301.8% | -72.9% | +12.6% | -499.4% | +116.1% | -91.5% | -255.2% | +933.3% | -43.2% | -241.3% |
| YoY Change | — | — | — | -213.2% | -26.8% | — | +231.6% | +169.0% | +209.9% | -221.8% | -27.8% | -94.6% | — | +117.5% | -37.9% | <-999% |
We use cookies for analytics. See our Privacy and Cookie Policy.